A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics

Ruki Wijesinghe, PharmD, BCPP

Abstract

Introduction: Antipsychotics are widely used and often in combination with other drugs, thereby frequently subjected to drug-drug interactions. This review will provide a summary of potential pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions associated with antipsychotic drugs.

Methods: A literature search was conducted for clinically significant drug interactions with antipsychotics.

Results: Most common PK drug interactions take place via the cytochrome P450 (CYP) system. PK profiles of first generation antipsychotics are inadequately studied; nevertheless most common drug interactions involve changes to their metabolic processes. Interactions with second generation antipsychotics are somewhat well-established, documented, and give some guidance for therapeutic treatment interventions. PD interactions occurring at the receptor level result in additive, synergistic, or antagonistic effects.

Discussion: This review summarizes a collection of relevant literature of significant PK and PD interactions occurring with antipsychotics. The involvement of multiple CYP enzymes makes it more difficult to predict the extent of the interaction and clinicians should take into consideration the timeline when evaluating potential interactions.

Keywords: pharmacokinetic, pharmacodynamic, antipsychotic, drug interactions

Introduction

Antipsychotics are widely used in patients who suffer from schizophrenia, bipolar disorder, and other psychiatric illnesses, often long term as these conditions are chronic, treatment resistant, or lifelong. As a disease worsens, antipsychotics are often used in combination with other psychotropic medications. Thus, the likelihood of drug interactions increases and may result in complex and unpredictable outcomes. Clinicians should have a good understanding of these drug interactions to maximize the therapeutic benefit and minimize side effects. The aim of this article is to review significant pharmacokinetic (PK) and pharmacodynamic (PD) interactions with antipsychotics.
| Antipsychotic | Metabolism | Pharmacokinetic Interaction With FGA |
|--------------|------------|-----------------------------------|
| Chlorpromazine Oral: tablet | Extensive CYP2D6 (major)– and CYP1A2 (minor)–mediated metabolism to several active and inactive metabolites. | CYP2A2 inhibitors (eg, ciprofloxacin, fluvoxamine) and CYP2D6 inhibitors (eg, paroxetine, fluoxetine) can reduce chlorpromazine clearance. Patients may experience chlorpromazine dose-dependent adverse drug reactions. |
| Fluphenazine Oral: elixir, solution, tablet | Extensive CYP2D6 metabolism. | Fluphenazine, a substrate and an inhibitor of CYP2D6, may inhibit its own metabolism. The plasma concentrations and the effects of fluphenazine may therefore be increased and prolonged by drugs that are either substrates or inhibitors of CYP2D6. |
| Haloperidol Oral: tablet, solution | Primarily hepatic clearance is by glucuronidation, followed by CYP3A4-mediated reduction. Some metabolites are potentially active. | Haloperidol is a substrate and an inhibitor of CYP3A4 and CYP2D6. Reduced haloperidol is also a substrate of CYP3A4 and an inhibitor of CYP2D6. Interactions with most drugs lead to only small changes in plasma haloperidol concentrations, suggesting that the interactions have little clinical significance. However, it is expected that co-administration of carbamazepine, phenytoin, phenobarbital, rifampin, or quinidine may alter PK of haloperidol resulting in clinical changes. |
| Perphenazine Oral: tablet | CYP2D6-mediated hydroxylation to active and inactive metabolites. | Drugs that inhibit CYP2D6 (eg, TCAs, fluoxetine, sertraline, paroxetine) may acutely increase plasma concentrations of perphenazine. Dose reductions and close monitoring may be necessary. |
| Pimozide Oral: tablet | Extensive dealkylation primarily by CYP3A4 and to a lesser extent by CYP 1A2, 2D6 to 2 other metabolites. | Manufacturer contraindicates the concomitant administration with CYP3A4 inhibitors: macrolide antibiotics (eg, clarithromycin, erythromycin, azithromycin),azole antifungals (eg, itraconazole, ketoconazole), protease inhibitors (eg, ritonavir, saquinavir, indinavir, nelfinavir), and nefazodone. Concomitant use with citalopram, escitalopram, paroxetine, sertraline, and other strong CYP2D6 inhibitors is also contraindicated. CYP2A4 and 2D6 enzyme inhibition may impede pimozide metabolism, leading to QT prolongation. Grapefruit juice may inhibit the metabolism of pimozide via CYP3A4 and cause QT prolongation. The effect of fluvoxamine (25 mg twice daily for 1 week) on thioridazine steady-state concentration was evaluated in 10 male inpatients with schizophrenia. Concentrations of thioridazine and its 2 active metabolites, mesoridazine and sulforidazine, increased 3-fold. Co-administration should be avoided. Concurrent administration of propranolol (100-800 mg daily) has been reported to produce increases in plasma levels of thioridazine (approximately 50%-400%) and its metabolites (approximately 80%-300%). Co-administration should be avoided. Concurrent administration of pindolol and thioridazine have resulted in moderate, dose-related increases in the serum levels of thioridazine and 2 of its metabolites, as well as higher than expected serum pindolol levels. Co-administration should be avoided. |
| Thioridazine Oral: tablet | Hydroxylation dependent on the level of CYP2D6 isozyme activity. Active metabolite mesoridazine (no longer available in the United States). | |
Pharmacokinetic Interactions With First-Generation Antipsychotics

Pharmacokinetic profiles of first-generation antipsychotics (FGAs) are not well described in the literature. Many of their potential metabolites remain undiscovered or their physiological activity inadequately studied. Nonetheless, general statements can be made when comparing the conventional antipsychotics as a group. All FGAs are well absorbed, with peak concentrations obtained 1 to 4 hours after oral administration. They attain clinical efficacy of improving illness symptoms of schizophrenia as rapidly as 15 minutes. Most FGAs are highly protein bound (85%-90%), and although changes in protein binding can have an influence on individual PK parameters, those changes caused by drug-drug interactions will usually not influence the clinical exposure of a patient, and no routine adjustments in dosing regimen are necessary.

Oral formulations undergo extensive liver metabolic transformations including glucuronidation, oxidation, reduction, and methylation. Most FGAs are metabolized by the cytochrome P450 (CYP) system, and most common PK drug-drug interactions involve effects on metabolism via the CYP system as listed in Table 1. Because of the many active metabolites and biological variability, there exist differences of the clinical response among FGAs and significant difficulty in predicting those interactions most likely to cause harm if not detected. The elimination half-lives of FGAs vary from 18 to 40 hours, and steady-state levels of oral drugs are reached in approximately 3 to 8 days. Numerous factors such as genetically determined metabolic rates, age, and co-administration of other hepatically metabolized drugs affect the half-life to such a degree that plasma levels may vary among individuals by 10- to 20-fold. The major routes of excretion are through urine and feces by way of bile, with minor pathways of excretion via sweat, saliva, tears, and breast milk.

Pharmacokinetic Interactions With Second-Generation Antipsychotics

Most PK interactions with second-generation antipsychotics (SGAs) arise at the stage of drug metabolism and usually involve changes to drug-metabolizing enzymes when other psychotropic agents or medications in the treatment of concomitant medical illness are added. A summary of PK drug interactions related to metabolism is presented in Table 2. In addition to drug-drug interactions related to the metabolism of SGA discussed in Table 2, it is important to take into consideration PK interactions consisting of changes in the absorption, distribution, or elimination of the antipsychotic that may result after the addition of another chemical agent.

In theory, studies of PK interactions conducted during the drug-development stage in a controlled environment in animal models, and thereafter in healthy volunteers using population PK modeling, are unambiguous; however, in reality, it is prudent to keep in mind that the interactions may be multifactorial. For example, formulation and drug-molecule differences, food-dependent absorption, lipophilicity resulting in high volume of distributions, and competition for protein binding leading to subsequent displacement interactions interfere with PK. In addition, the state of the hepatic portal system and a patient’s genetic variability, which in turn may affect the drug’s hepatic and renal clearance, play important roles, resulting in clinically significant drug interactions.

Pharmacodynamic Interactions

Pharmacodynamic drug-drug interactions occur when drugs being added to the antipsychotic compete at the receptor level, interfering with the therapeutic efficacy or perhaps contributing to an adverse effect. For example, when levodopa, a drug used for Parkinsonism with agonistic action at dopamine D2 receptor is added, the antipsychotic through its dopamine antagonism can oppose the effects of levodopa. The result may culminate in worsening motor function, a relapse of psychosis or a combination thereof.

Table 3 lists several examples of PD interactions resulting in antagonistic, additive, or synergistic effects most often leading to adverse effects but, at times, rarely and deliberately augmented to obtain a favorable effect.

Discussion

Nondrug patient factors (such as age, sex, concomitant diseases, genetic polymorphisms, caffeine and drug intake

---

**TABLE 1: First-generation antipsychotic metabolism and the potential for drug interactions**

| Antipsychotic | Metabolism | Pharmacokinetic Interaction With FGA |
|---------------|------------|-------------------------------------|
| Trifluoperazine Oral: tablet | Extensive hepatic metabolism by CYP1A2. | Trifluoperazine levels may be increased by CYP1A2 strong inhibitors. Smoking (CYP1A2 inducer) may decrease levels of trifluoperazine. |

CYP = cytochrome P450; FGA = first-generation antipsychotic; IV = intravenous; PK = pharmacokinetics; QT = QT interval on the electrocardiogram; TCA = tricyclic antidepressant.
| Antipsychotic   | Metabolism                                                                 | Pharmacokinetic Interaction With Second-Generation Antipsychotic |
|----------------|---------------------------------------------------------------------------|---------------------------------------------------------------|
| Aripiprazole   | CYP2D6, 3A4 catalyze dehydrogenation to active dehydroaripiprazole. Does not undergo glucuronidation. | CYP3A4 inducers lower aripiprazole levels by about 60%, while CYP2D6 inhibitors increase levels by about 45%. Ketokonazole and quinidine decrease aripiprazole metabolism, so aripiprazole dose should be decreased by half during co-administration. Although itraconazole is a potent CYP3A4 inhibitor, there was no clinically significant difference in one small study (n = 24). Carbamazepine reduces aripiprazole and metabolite levels by 70%, so aripiprazole doses may need to be doubled when added to carbamazepine and halved when carbamazepine is discontinued. |
| Asenapine      | Direct glucuronidation by UGT1A4 and oxidative metabolism by CYP1A2.        | Fluvoxamine increases plasma concentration of asenapine by 29%. Should be co-administered with caution, while observing for adverse effects such as drowsiness, dizziness, and increased appetite. Asenapine (CYP2D6 inhibitor) increases paroxetine levels 2-fold. |
| Clozapine      | Extensive first-pass in the liver and gut; predominantly metabolized by CYP1A2, 2D6. Also, contributed by CYP3A4 to active norclozapine. | Caffeine and clozapine are both metabolized by CYP1A2, and caffeine at 400 to 1000 mg may competitively inhibit clozapine metabolism with significant increase (26%) in clozapine levels. Fluoxetine, possibly by CYP2D6 inhibition increases clozapine and norclozapine levels. It is suggested that measuring clozapine levels may be useful. Fluvoxamine inhibition of CYP1A2 leads to a significant increase in clozapine levels. Paroxetine significantly increases plasma clozapine and norclozapine levels and may expose to clozapine toxicity. Sertraline may produce significant increases in plasma clozapine levels—the risk of clozapine toxicity should be considered. Phenytoin may reduce serum concentrations of clozapine via CYP1A2 induction. Cimetidine may increase clozapine levels by 50%. Ranitidine is a safer alternative. Digoxin and warfarin are highly protein-bound drugs. Dose should be monitored and adjusted as necessary. |
| Iloperidone    | Extensive hepatic metabolism via carbonyl reduction, hydroxylation (CYP2D6), and O-demethylation (CYP3A4); forms active metabolites. | Iloperidone dose should be decreased by 50% with strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine), and when CYP2D6 inhibitor is discontinued return to previous dose. Iloperidone dose should be decreased by 50% with strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin) and when CYP3A4 inhibitor is discontinued return to previous dose. Iloperidone dose should be decreased by 50% in poor metabolizers of CYP2D6. |
| Antipsychotic | Metabolism | Pharmacokinetic Interaction With Second-Generation Antipsychotic |
|--------------|------------|---------------------------------------------------------------|
| Lurasidone   | Primarily via CYP3A4 to 2 active metabolites (main: exo-hydroxy metabolite). | Contraindicated with strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, voriconazole) as they elevate lurasidone levels, and inducers (eg, rifampin, carbamazepine, phenytoin, St John’s wort) as they decrease lurasidone levels. Lurasidone dose should be reduced to half the original dose if prescribed concomitantly with a moderate CYP3A4 inhibitor (eg, diltiazem, atazanavir, erythromycin, fluconazole, verapamil). Manufacturer recommends avoiding grapefruit and grapefruit juice. |
| Olanzapine   | Highly metabolized via direct glucuronidation by UGT1A4 and CYP3A4, 2D6-mediated oxidation to inactive metabolites; 40% removed via first-pass metabolism. | Fluvoxamine (100 mg/d) inhibits olanzapine metabolism raising olanzapine peak levels by 49%, AUC by 70%, half-life by 40%, and steady-state levels by 22%-112%. Smoking increases olanzapine clearance by 40%. Olanzapine clearance decreased by 30% in females. PK do not differ significantly between extensive and poor CYP2D6 metabolizers. |
| Paliperidone | Hepatic metabolism via CYP2D6 and CYP3A4 (limited role in elimination); minor metabolism (<10%) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. | Carbamazepine, a strong inducer of both CYP3A4 and P-gp, decreased the AUC by 37%. In vitro studies have shown that paliperidone is a P-gp substrate. Paroxetine, a potent CYP2D6 inhibitor, increased paliperidone on average 16%, but the clinical relevance is unknown. |
| Quetiapine   | Primarily hepatic metabolism via CYP3A4 to active N-desalkyl quetiapine and 2 inactive metabolites. Metabolism reduced by ~30% with advancing age. | Carbamazepine, phenytoin, rifampin, and St John’s wort will increase quetiapine clearance. Up to a 5-fold increase of the original quetiapine dose is advised by the manufacturer if used in combination long term (>7-14 days); also advised is to reduce quetiapine dose accordingly upon discontinuation of strong CYP3A4 inducers. CYP3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, and nefazodone may increase quetiapine levels. The manufacturer advises a reduction in the quetiapine dose to one sixth if used concomitantly. |
| Risperidone  | Extensive metabolism via CYP3A4 and CYP2D6 to 9-hydroxyrisperidone (active); N-dealkylation as a minor pathway. | Risperidone dose should be increased and titrated up to double the patient’s usual dose when adding to carbamazepine and other inducers. The initial dose of risperidone should be reduced (max = 8 mg per day) with CYP2D6 inhibitors such as fluoxetine and paroxetine. |
| Ziprasidone  | Extensive hepatic metabolism via aldehyde oxidase to active S-methyl-dihydroziprasidone; less than one third of total metabolism via CYP3A4 and CYP2A2 (minor). | CYP-enzyme inducers and inhibitors have little potential for clinically important PK interactions with ziprasidone. Literature reports no clinically significant inhibitors of aldehyde oxidase, suggesting less drug-drug interactions. |

AUC = area under the curve; Cmax = peak serum drug concentration; CYP = cytochrome P450; ER = extended release; IR = immediate release; P-gp = P-glycoprotein transporter; PK = pharmacokinetics; SGA = second-generation antipsychotic; UGT = uridine 5'-diphosphate-glucuronosyltransferases.
| Possible PD Interaction                                      | High-Risk Antipsychotic(s) | Combined Drug or Classa |
|-------------------------------------------------------------|----------------------------|-------------------------|
| Anticholinergic and related side effects: blurred vision, constipation, dry mouth, urinary retention, confusion | Chlorpromazine, Clozapine, Pimozide, Trifluoperazine | Anticholinergic drugs (eg, hyoscine, atropine) Tricyclic antidepressants |
| Blood dyscrasias: neutropenia/ agranulocytosis              | Clozapine                 | Antibiotics reported to cause leukopenia/ neutropenia: clindamycin, sulphonamides, ciprofloxacin, erythromycin, metronidazole Carbamazepine Carbimazole Chloramphenicol Cytotoxics Lithium (increases neutrophil count but does not protect against agranulocytosis) Long-acting depot antipsychotics Penicillamine Phenylbutazone |
| Metabolic changes and weight gain                           | Chlorpromazine, Clozapine, Olanzapine, Perphenazine, Phenothiazines | Antipsychotics Lithium Metformin or topiramate added to an antipsychotic may result in weight loss Mirtazapine Tricyclic antidepressants Valproic acid |
| Sedation                                                    | Chlorpromazine, Clozapine, Olanzapine, Quetiapine | Alcohol Antihistamines Benzodiazepines Mirtazapine Opioids Sedative hypnotics Trazodone Tricyclic antidepressants: higher incidence with amitriptyline |
| Sedation and cardiorespiratory depression                   | Short-acting intramuscular olanzapine | Intramuscular lorazepam |
| Seizures                                                    | Chlorpromazine, Clozapine, Most phenothiazines | Bupropion Sudden alcohol and benzodiazepine withdrawal Trazodone Tricyclic antidepressants |
| Orthostatic hypotension and related falls                   | Asenapine, Clozapine, Iloperidone, Olanzapine, Risperidone | Alcohol Antihypertensives Tricyclic antidepressants |
| QT prolongation                                             | Haloperidol, Pimozide, Thioridazine, Ziprasidone, Recent dose increase or high doses of antipsychotic (including overdose), Intravenous antipsychotic(s) | Amantadine Antiarrhythmics: quinidine, disopyramide, procainamide, sotalol, amiodarone, dofetilide Antibiotics: erythromycin, clarithromycin, trimethoprim-sulfamethoxazole, pentamidine, levofloxacin, moxifloxacin Antifungals: fluconazole, ketoconazole Antimalarials: chloroquine, mefloquine, quinine Citalopram Cyclosporine Diphenhydramine Escitalopram Hydroxyzine Methadone Tamoxifen Tricyclic antidepressants |

PD = pharmacodynamics; QT = QT interval on the electrocardiogram.

*More updated and current lists can be accessed via [www.torsades.org](http://www.torsades.org) or [www.qtdrugs.org](http://www.qtdrugs.org).*
habits, and use of herbal medications) as well as drug-related factors (such as formulation, dose, and route of administration) contributing to antipsychotic drug interactions are beyond the scope of this review; nevertheless, these factors should be taken into consideration when assessing PK- and PD-drug interactions comprehensively. Some studies find proposed PK principles lacking a significant impact on the plasma levels of the antipsychotic, suggesting that theoretical drug interactions may not always occur as anticipated. In addition, researchers suggest that multiple CYP enzyme involvement in an antipsychotic metabolism will make it more difficult to predict the extent of the drug interaction because at low doses one type of CYP metabolism may predominate, while at higher doses another CYP enzyme interaction may possibly be prominent. 1

During this review, it is also noted that newer antipsychotics introduced in recent years have more-specific, standardized PK information and recommendations in their product labeling compared with those agents marketed decades ago. However, there is little information on monitoring of plasma concentration levels to gauge the response of a drug interaction. The blood-brain distribution of the antipsychotic drugs or their potentially active metabolites may or may not contribute to varying plasma concentrations among individuals, suggesting that plasma levels may not be a useful measure in evaluating PK and PD interactions. Moreover, the time course of the drug interactions are rarely mentioned in literature, but clinicians should take into consideration the timeline (eg, half-life, time for steady state) when evaluating potential PK and PD interactions especially in patients on multiple and long-term drug treatment. Lastly, avoidance of unnecessary polypharmacy, knowledge of drug-interaction profiles, experience, and good clinical judgement are essential in preventing significant and potentially adverse PK- and PD-drug interactions in patients receiving antipsychotics.

References

1. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27(12):1021-48. DOI: 10.1007/s40263-013-0114-6.
2. Bleakley S. Identifying and reducing the risk of antipsychotic drug interactions. Prog Neurol Psychiatry. 2012;16(2):20-4. DOI: 10.1002/pnp.231.
3. Schatzberg AF, Nemeroff CB. Essentials of clinical psychopharmacology. 3rd ed. Arlington (VA): American Psychiatric Publishing; 2013.
4. Benet L. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115-21. DOI: 10.1067/ mcp.2002.121829.
5. American Pharmacists Association. Drug information handbook with international trade names index. 21st ed. Hudson (OH): Lexi-Comp; 2012.
6. Sanofi-aventis, New Zealand Ltd. Largactil (chlorpromazine hydrochloride). [rev 2013 Feb; cited 2014 Dec 21]. Available from: http://www.medsafe.govt.nz/profs/datasheet/l/largactiltabinjsusp.pdf
7. Mylan Pharmaceuticals Inc. Fluphenazine hydrochloride. [rev 2010 Feb; cited 2014 Dec 21]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33bffb02-f1cc-4554-a3b7-9f2291febf4c
8. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435-56. DOI: 10.2165/00003088-19993706-00001.
9. Sandoz Inc. Perphenazine. [rev 2013 Dec; cited 2014 Dec 21]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c76e98d-b8c3-441f-bac5-agde6dcb74
10. Teva Select Brands. ORAP (Pimozide). [rev 2014 Oct; cited 2014 Dec 21]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9729c3-545f-4034-9bc7-72b6e028fc4
11. Remedyrepack Inc. Thoridazine hydrochloride. [rev 2011 Apr; cited 2014 Dec 21]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f916dfb5-15fc-408f-b874-5656ae8b7043
12. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin Pharmacol Toxicol. 2007;100(4):4-22. DOI: 10.1111/j.1742-7843.2007.00017.x. PubMed PMID: 17712606.
13. Bazire S. Psychotropic drug directory 2014. Warwickshire, UK: Lloyd-Reinhold Communications LLP; 2014.
14. Stockley’s Drug Interactions [Internet]. The Pharmaceutical Press; MedicinesComplete 2015; Royal Pharmaceutical Society [updated 2015 Feb; cited 2015 May 9]. Available from: https://www.medicinescomplete.com/mc/stockley/current/
15. Letsas KP, Efremidis M, Filippatos GS, Sideris AM. Drug-induced long QT syndrome. Hellenic J Cardiol. 2007;48:296-9. PubMed PMID: 17966685.
16. Coates TD. Drug-induced neutropenia and agranulocytosis. In: Boxer LA, ed. UpToDate [Internet]. 2014, [cited 2014 Dec 16]. Available from: http://www.uptodate.com/contents/drug-induced-neutropenia-and-agarulocytosis
17. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1-13. DOI: 10.1016/j. psym.2012.11.001.
18. Taylor D, Paton C, Kapur S, editors. The Maudsley prescribing guidelines in psychiatry. 11th ed. West Sussex, UK: John Wiley & Sons; 2012.